Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 392

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

Open access
Suzuki, Shigeaki, Ishikawa, Nobuhisa, Konoeda, Fumie, Seki, Nobuhiko, Fukushima, Satoshi, Takahashi, Kikuko, Uhara, Hisashi, Hasegawa, Yoshikazu, Inomata, Shinichiro, Otani, Yasushi, Yokota, Kenji, Hirose, Takashi, Tanaka, Ryo, Suzuki, Norihiro, Matsui, Makoto·2017·Neurology

Abstract

OBJECTIVE: To report the clinical features of myasthenia gravis (MG) induced by treatment with immune checkpoint inhibitors using 2-year safety databases based on postmarketing surveys in Japan. METHODS: We studied 10,277 patients with cancer who had received monotherapy with either nivolumab or ipilimumab between September 2014 and August 2016. As the control group, 105 patients with idiopathic MG were used. RESULTS: There were 12 MG cases (0.12%) among 9,869 patients with cancer who had been treated with nivolumab, but none among 408 patients treated with ipilimumab. These 12 patients included 6 men and 6 women with a mean age of 73.5 ± 6.3 years. MG onset occurred in the early phase after nivolumab treatment and rapidly deteriorated. Nivolumab-related MG (nivoMG) included 4 patients with mild involvement and 8 patients with severe involvement. Bulbar symptoms and myasthenic crisis were observed more frequently in nivoMG than idiopathic MG. Ten patients were positive for anti-acetylcholine receptor antibodies. Serum creatine kinase levels were markedly elevated to an average level of 4,799 IU/L. Among the 12 patients with nivoMG, 4 had myositis and 3 had myocarditis, with 1 of these patients having both. Immunosuppressive therapy was effective. Postintervention status showed that pharmacologic remission or minimal manifestations were obtained in 4 patients; however, 2 patients died. Immune-related adverse events triggered by nivolumab impaired the patients' daily living activity. CONCLUSIONS: The prompt and correct recognition of MG following treatment with immune checkpoint inhibitors in patients with cancer is important.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000004359

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 392

Metadata

Authors
Suzuki, S., Ishikawa, N., Konoeda, F., Seki, N., Fukushima, S., Takahashi, K., Uhara, H., Hasegawa, Y., Inomata, S., Otani, Y., Yokota, K., Hirose, T., Tanaka, R., Suzuki, N., & Matsui, M.
Venue
Neurology
Published
2017-09-12
Volume
89
Issue
11
Pages
1127-1134
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2747440871
Cited by
392
References
22
FWCI
27.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. https://app.cochat.ai/papers/10.1212/wnl.0000000000004359
The paper
Suzuki, S., Ishikawa, N., Konoeda, F., Seki, N., Fukushima, S., Takahashi, K., Uhara, H., Hasegawa, Y., Inomata, S., Otani, Y., Yokota, K., Hirose, T., Tanaka, R., Suzuki, N., & Matsui, M. (2017). Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. https://doi.org/10.1212/wnl.0000000000004359

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.